These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30464124)

  • 1. Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI.
    Liu X; Hu Y; Huang W; Zhang G; Cao S; Yan X; Li L; Zhang L; Zheng X
    Int Heart J; 2019 Jan; 60(1):19-26. PubMed ID: 30464124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP.
    Yu J; Oh PC; Kim M; Moon J; Park YM; Lee K; Suh SY; Han SH; Byun K; Ahn T; Kang WC
    PLoS One; 2017; 12(8):e0182829. PubMed ID: 28796845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of galectin-3 and soluble ST2 with in-hospital and 1-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Maksym J; Balsam P; Opolski G; Filipiak KJ
    Pol Arch Intern Med; 2019 Nov; 129(11):770-780. PubMed ID: 31642446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction.
    Huang WP; Zheng X; He L; Su X; Liu CW; Wu MX
    Chin Med J (Engl); 2018 Jun; 131(11):1282-1288. PubMed ID: 29786039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Somuncu MU; Akgun T; Cakır MO; Akgul F; Serbest NG; Karakurt H; Can M; Demir AR
    J Atheroscler Thromb; 2019 Nov; 26(11):970-978. PubMed ID: 30996145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention.
    Zhang Q; Hu M; Ma S
    J Atheroscler Thromb; 2021 Dec; 28(12):1289-1297. PubMed ID: 33551392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective.
    Jenkins WS; Roger VL; Jaffe AS; Weston SA; AbouEzzeddine OF; Jiang R; Manemann SM; Enriquez-Sarano M
    Am J Med; 2017 Sep; 130(9):1112.e9-1112.e15. PubMed ID: 28344136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic changes in soluble suppression of tumorigenicity 2 levels predict major adverse cardiovascular events in patients with ST‑segment elevation myocardial infarction.
    Liu L; Li S; Ding X; Wang D; Li W; Li H
    Pol Arch Intern Med; 2022 Oct; 132(10):. PubMed ID: 35984957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction.
    Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Balsam P; Opolski G; Filipiak KJ
    Dis Markers; 2019; 2019():9529053. PubMed ID: 31687050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of myeloperoxidase concentration in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Kacprzak M; Zielinska M
    Int J Cardiol; 2016 Nov; 223():452-457. PubMed ID: 27544604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of apelin-12 in patients with ST-elevation myocardial infarction with different renal function: a prospective observational study.
    Yang L; Zheng T; Wu H; Xin W; Mou X; Lin H; Chen Y; Wu X
    BMJ Open; 2017 Nov; 7(11):e018595. PubMed ID: 29150476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [BIOMARKER ST2 AS A NEW PREDICTOR OF ACUTE KIDNEY INJURY IN PATIENTS WITH ACUTE ST SEGMENT ELEVATION MYOCARDIAL INFARCTION].
    Kopytsya M; Hilova Y; Vyshnevska I; Petyunina O
    Georgian Med News; 2018 Sep; (282):61-65. PubMed ID: 30358542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of soluble suppression of tumourigenicity 2 on myocardial reperfusion.
    Bai S; Liu H; Wu H; Wang X; Li R; Li X; Li X; Zhang L; Chen T; Du R
    Intern Med J; 2020 Aug; 50(8):985-992. PubMed ID: 31566840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plaque characteristics and inflammatory markers for the prediction of major cardiovascular events in patients with ST-segment elevation myocardial infarction.
    Her AY; Cho KI; Singh GB; An DS; Jeong YH; Koo BK; Shin ES
    Int J Cardiovasc Imaging; 2017 Oct; 33(10):1445-1454. PubMed ID: 28555389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction.
    Kim M; Lee DI; Lee JH; Kim SM; Lee SY; Hwang KK; Kim DW; Cho MC; Bae JW
    Cardiol J; 2021; 28(2):244-254. PubMed ID: 32104902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
    Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of admission red cell distribution width-to-platelet ratio in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Pusuroglu H; Cakmak HA; Akgul O; Erturk M; Surgit O; Akkaya E; Bulut U; Yildirim A
    Rev Port Cardiol; 2015 Oct; 34(10):597-606. PubMed ID: 26387826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Admission macrophage migration inhibitory factor predicts long-term prognosis in patients with ST-elevation myocardial infarction.
    Deng XN; Wang XY; Yu HY; Chen SM; Xu XY; Huai W; Liu GH; Ma QB; Zhang YY; Dart AM; Du XJ; Gao W
    Eur Heart J Qual Care Clin Outcomes; 2018 Jul; 4(3):208-219. PubMed ID: 29726987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes.
    Jha D; Goenka L; Ramamoorthy T; Sharma M; Dhandapani VE; George M
    Eur J Clin Invest; 2018 Sep; 48(9):e12994. PubMed ID: 29992539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of serum transaminases with short- and long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Gao M; Cheng Y; Zheng Y; Zhang W; Wang L; Qin L
    BMC Cardiovasc Disord; 2017 Jan; 17(1):43. PubMed ID: 28129742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.